{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T05:48:00Z","timestamp":1757310480911},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,8,3]],"date-time":"2018-08-03T00:00:00Z","timestamp":1533254400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Rheumatol"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s42358-018-0016-x","type":"journal-article","created":{"date-parts":[[2018,8,3]],"date-time":"2018-08-03T14:29:33Z","timestamp":1533306573000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Evaluation of the safety and satisfaction of rheumatic patients with accelerated infliximab infusion"],"prefix":"10.1186","volume":"58","author":[{"given":"Joz\u00e9lio Freire","family":"de Carvalho","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Natividade Pereira","family":"dos Santos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joyce Meyre Vieira","family":"de Oliveira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea Nogueira S.","family":"Lanty Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto Paulo Correia","family":"de Araujo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juliana Bahia","family":"Cardozo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,8,3]]},"reference":[{"key":"16_CR1","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1590\/S0482-50042011000200005","volume":"51","author":"DC Titton","year":"2011","unstructured":"Titton DC, Silveira IG, Louzada-Junior P, Hayata AL, Carvalho HM, et al. Brazilian biologic registry: BiobadaBrasil implementation process and preliminary results. Rev Bras Reumatol. 2011;51:152\u201360.","journal-title":"Rev Bras Reumatol"},{"key":"16_CR2","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1590\/S0482-50042010000200006","volume":"50","author":"JC de Moraes","year":"2010","unstructured":"de Moraes JC, Aikawa NE, Ribeiro AC, Saad CG, Carvalho JF, Pereira RM, Silva CA, Bonf\u00e1 E. Immediate complications of 3,555 injections of anti-TNF\u03b1. Rev Bras Reumatol. 2010;50:165\u201375.","journal-title":"Rev Bras Reumatol"},{"key":"16_CR3","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1111\/apt.12389","volume":"38","author":"HC Neef","year":"2013","unstructured":"Neef HC, Riebschleger MP, Adler J. Meta-analysis: rapid IFX infusions are safe. Alimentary Pharmacology and Therapeuticc. 2013;38:365\u201376.","journal-title":"Alimentary Pharmacology and Therapeuticc"},{"key":"16_CR4","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/S1699-258X(07)73616-1","volume":"3","author":"D Ba\u00f1uelos-Ram\u00edrez","year":"2007","unstructured":"Ba\u00f1uelos-Ram\u00edrez D, Ramirez-Palma MM, Balcazar-Sanchez ME, Sanchez-Alonso S. Rapid application of infliximab. Efficacy complications. Reumatol Clin. 2007;3:171\u20135.","journal-title":"Reumatol Clin"},{"key":"16_CR5","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1093\/rheumatology\/kei247","volume":"45","author":"MH Buch","year":"2006","unstructured":"Buch MH, Bryer D, Lindsay S, Rees-Evans B, Fairclough A, Emery P. Shortening infusion times for infliximab administration. Rheumatology (Oxford). 2006;45:485\u20136.","journal-title":"Rheumatology (Oxford)"},{"key":"16_CR6","first-page":"97\u201397","volume":"50","author":"Y El Miedany","year":"2011","unstructured":"El Miedany Y, Palmer D. Infliximab infusion therapy in inflammatory arthritis: assessment of the accelerated infusion protocol in comparison to the standard infusion approach. Rheumatology (Oxford). 2011;50:97\u201397.","journal-title":"Rheumatology (Oxford)"},{"key":"16_CR7","first-page":"667","volume":"29","author":"WJ hergy","year":"2002","unstructured":"hergy WJ, Isern RA, Cooley DA, et al. Open label study to assess infliximab safety and timing of onset of clinical benefit among patients with rheumatoid arthritis. J Rheumatol. 2002;29:667\u201377.","journal-title":"J Rheumatol"},{"key":"16_CR8","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1111\/j.1365-2036.2011.04699.x","volume":"34","author":"TW Lee","year":"2011","unstructured":"Lee TW, Singh R, Fedorak RN. A one-hour infusion of infliximab during maintenance therapy is safe and well tolerated: a prospective cohort study. Aliment Pharmacol Ther. 2011;34:181.","journal-title":"Aliment Pharmacol Ther"},{"key":"16_CR9","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/art.1780310302","volume":"31","author":"FC Arnett","year":"1988","unstructured":"Arnett FC, Edworthy SM, Bloch DA, Mcshane DJ, Fries JF, Coope NS, et al. The American rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315\u201324.","journal-title":"Arthritis Rheum"},{"key":"16_CR10","first-page":"456","volume-title":"Population studies of the rheumatic diseases","author":"PH Bennett","year":"1968","unstructured":"Bennett PH, Wood PHN. Population studies of the rheumatic diseases. New York: Excerpta Medica; 1968. p. 456."},{"key":"16_CR11","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/0049-0172(73)90035-8","volume":"3","author":"JM Moll","year":"1973","unstructured":"Moll JM, Wright V. Psoriatic arthritis. Semin Arthritis Rheum. 1973;3:55\u201378.","journal-title":"Semin Arthritis Rheum"},{"key":"16_CR12","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1002\/art.1780341003","volume":"34","author":"M Dougados","year":"1991","unstructured":"Dougados M, vander Linden S, Juhlin R, Huitfeldt B, Amor B, Calin A, et al. The European Spondylarthropathy study group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum. 1991;34:1218\u201327.","journal-title":"Arthritis Rheum"},{"key":"16_CR13","first-page":"355","volume":"30","author":"Protocolo de actua\u00e7\u00e3o em caso de reac\u00e7\u00e3o \u00e0 infus\u00e3o de infliximab","year":"2005","unstructured":"Protocolo de actua\u00e7\u00e3o em caso de reac\u00e7\u00e3o \u00e0 infus\u00e3o de infliximab. Grupo de Estudos de Artrite Reumatoide da Sociedade Portuguesa de Reumatologia. Acta Reum Port. 2005;30:355\u20139.","journal-title":"Acta Reum Port"},{"key":"16_CR14","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1038\/ajg.2011.211","volume":"106","author":"G Van Assche","year":"2011","unstructured":"Van Assche G, Lewis JD, Lichtenstein GR, et al. The London position statement of the world congress of gastroenterology on biological therapy for IBD with the European Crohn's and colitis organisation: safety. Am J Gastroenterol. 2011;106:1594\u2013602.","journal-title":"Am J Gastroenterol"},{"key":"16_CR15","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1007\/s12325-009-0069-7","volume":"26","author":"SV Kane","year":"2009","unstructured":"Kane SV, Chao J, Mulani PM. Adherence to infliximab maintenance therapy and health care utilization and costs by Crohn\u2019s disease patients. Adv Ther. 2009;26:936\u201346.","journal-title":"Adv Ther"}],"container-title":["Advances in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s42358-018-0016-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s42358-018-0016-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s42358-018-0016-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,2]],"date-time":"2019-08-02T23:15:27Z","timestamp":1564787727000},"score":1,"resource":{"primary":{"URL":"https:\/\/advancesinrheumatology.biomedcentral.com\/articles\/10.1186\/s42358-018-0016-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,3]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["16"],"URL":"https:\/\/doi.org\/10.1186\/s42358-018-0016-x","relation":{},"ISSN":["2523-3106"],"issn-type":[{"value":"2523-3106","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,3]]},"assertion":[{"value":"26 March 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"22"}}